Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Scientists have built the most detailed cellular map of childhood Crohn's disease yet, revealing which cell signatures predict disease severity and treatment response. Using single-cell RNA sequencing, researchers found that anti-TNF therapy may push the disease toward a more treatment-resistant, adult-like cellular state. A complementary study also uncovered "molecular scars" in gut stem cells that persist even after inflammation resolves.
Two new studies are giving researchers an unprecedented look at Crohn's disease at the single-cell level — and the findings could reshape how clinicians approach treatment, especially in kids.
A team from Boston Children's Hospital and Harvard Medical School built a comprehensive cellular atlas of pediatric Crohn's disease (pediCD), analyzing over 94,000 cells from newly diagnosed, untreated children before and after therapy. Using a novel bioinformatics tool called ARBOL, they identified specific cell signatures that predict disease severity and response to anti-TNF treatment. Strikingly, they found that anti-TNF therapy may push the childhood Crohn's cellular environment toward the more severe, treatment-resistant state typically seen in adult disease.
A complementary study from the Wellcome Sanger Institute analyzed over 1 million gut cells from 111 Crohn's patients and 232 healthy controls, creating an open-access resource called IBDverse. That study uncovered a "molecular scar" — inflammatory gene activity that persists in gut stem cells even after visible inflammation heals — and identified a macrophage population driving inflammation via the JAK/STAT pathway, a known target of existing IBD therapies.
Key Takeaways:
Why it matters: These atlases give clinicians and researchers a powerful new framework for predicting which pediatric patients will benefit from anti-TNF therapy — and which may need alternative strategies — potentially reducing unnecessary treatment exposure and improving long-term outcomes for children with Crohn's.
